Skip to main content
SpringerLink
Log in

ACE Inhibitor ARB Controversies

  • Chapter
  • First Online:
Book cover Cardiac Drug Therapy

Part of the book series: Contemporary Cardiology ((CONCARD))

  • 3479 Accesses

Abstract

Angiotensin-converting enzyme (ACE) inhibitors have been shown in large randomized controlled trials (RCTs) to prevent cardiovascular disease (CVD) outcomes significantly in patients with hypertension and heart failure (HF) and particularly in patients with LV dysfunction caused by acute myocardial infarction (MI). Some ARBs confer modest cardiovascular protection.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 139.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 179.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  • ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs. diuretic: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). JAMA. 2002;288:2981–97.

    Article  Google Scholar 

  • Casas JP, Chau W, Loukogeorgakis S, et al. Effect of inhibitors of the renin-angiotensin system and other antihypertensive drugs on renal outcomes: systematic review and meta-analysis. Lancet. 2005;366:2026–33.

    Article  CAS  PubMed  Google Scholar 

  • CHARM-Added trial, Swedberg K, Granger CB, McMurray JJV, et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors. Lancet. 2003;362:767–71.

    Article  PubMed  Google Scholar 

  • CHARM-Alternative, Granger CB, McMurray JJV, Yusuf S, et al. Effects of candesartan in patients with chronic heart failure and reduced left ventricular systolic function and intolerant to ACE inhibitors: the CHARM-alternative trial. Lancet. 2003;362(9386):772–6.

    Article  CAS  PubMed  Google Scholar 

  • DREAM Trial Investigators. Effect of ramipril on the incidence of diabetes. N Engl J Med. 2006;355:1551–62.

    Article  Google Scholar 

  • LIFE, Dahlöf B, Devereux RB, Kjeldsen SE, for the LIFE Study Group, et al. Cardiovascular morbidity and mortality in the Losartan Intervention for Endpoint Reduction in Hypertension study: a randomised trial against atenolol. Lancet. 2002;359:995–1003.

    Article  PubMed  Google Scholar 

  • Lindholm LH, Ibsen H, Borch-Johnsen K, et al. Risk of new-onset diabetes in the Losartan Intervention for Endpoint Reduction in Hypertension study. J Hypertens. 2002;20:1879–86.

    Article  CAS  PubMed  Google Scholar 

  • Nathan DM. Navigating the choices for diabetes prevention. NEJM. 2010;362:1533–5.

    Article  CAS  PubMed  Google Scholar 

  • NAVIGATOR Study Group. Effect of nateglinide on the incidence of diabetes and cardiovascular events. N Engl J Med. 2010a;362:1463–76.

    Article  Google Scholar 

  • NAVIGATOR Study Group. Effect of valsartan on the incidence of diabetes and cardiovascular events. N Engl J Med. 2010b;362:1477–90.

    Article  Google Scholar 

  • Pfeffer MA, McMurray JJV, Velazquez EJ, et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med. 2003;349:1893–906.

    Article  CAS  PubMed  Google Scholar 

  • Pitt B, Remme W, Zannad F, for the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study Investigators, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 2003;348:1309–21.

    Article  CAS  PubMed  Google Scholar 

  • Pitt B, Zannad F, Remme WJ, for the Randomized Evaluation Study Investigators, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med. 1999;341:709.

    Article  CAS  PubMed  Google Scholar 

  • PRoFESS, Yusuf S, Diener H-C, Sacco RL, et al. Telmisartan to prevent recurrent stroke and cardiovascular events. N Eng J Med. 2008;359(12):1225–37.

    Article  CAS  Google Scholar 

  • Sipahi I, Debanne SM, Rowland DY, Simon DI, Fang JC. Angiotensin-receptor blockade and risk of cancer: meta-analysis of randomised controlled trials. Lancet Oncol 2010;11:627–636.

    Google Scholar 

  • TRANSCEND, Yusuf S, Teo K, Anderson C, et al. Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin converting enzyme inhibitors: a randomised controlled trial. Lancet. 2008;372:1174–83.

    Article  CAS  PubMed  Google Scholar 

  • Val-HeFT, Cohn JN, Tognoni G, for the Valsartan Heart Failure Trial Investigators. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med. 2001;345:1667–675.

    Google Scholar 

  • VALIANT, Pfeffer MA, McMurray JJ, Velazquez EJ, et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med. 2003;349:1893–906.

    Article  CAS  PubMed  Google Scholar 

  • VALUE Trial Group, Julius S, Kjeldsen SE, Weber M, et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimes based on valsartan or amlodipine. Lancet. 2004;363:2002–31.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. University of Ottawa The Ottawa Hospital, Ottawa, ON, Canada

    M. Gabriel Khan MD, FRCPC, FRCP (London), FACC

Authors
  1. M. Gabriel Khan MD, FRCPC, FRCP (London), FACC
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

Copyright information

© 2015 Springer Science+Business Media New York

About this chapter

Cite this chapter

Khan, M.G. (2015). ACE Inhibitor ARB Controversies. In: Cardiac Drug Therapy. Contemporary Cardiology. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-61779-962-4_4

Download citation

  • DOI: https://doi.org/10.1007/978-1-61779-962-4_4

  • Published:

  • Publisher Name: Humana Press, Totowa, NJ

  • Print ISBN: 978-1-61779-961-7

  • Online ISBN: 978-1-61779-962-4

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation